

Vimian Group AB (publ) CEO to step down at the end of the year

Today, Vimian Group AB (publ) ("Vimian") announces that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end.

"Vimian has over the past three years transformed into a large, global company with a strong innovation pipeline and I am proud of what we have achieved together as a team. The past years have been very rewarding, but with significant time away from my family. All four segments are performing well under strong leadership teams, and I found the timing right to eventually hand over to a new CEO to take Vimian to the next level, but I am committed to secure a coordinated succession. Vimian is a truly exciting company in a growing market, and I remain an engaged shareholder", says Fredrik Ullman, CEO of Vimian Group.

"On behalf of the Board of Directors I would like to thank Fredrik for his valuable contributions to the Vimian journey. Under his tenure Vimian has more than doubled in size, entered new geographies, launched key innovation projects and built leading market positions in attractive global niches of the animal health market. The overall strategic agenda is the same and we remain focused on supporting veterinarians and pet owners with new innovative products and services. We entered the second quarter with continued growth and see significant unmet medical needs of many companion animals across the world", says Gabriel Fitzgerald, Chairman of the Board, Vimian Group.

The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.

For further information, please contact:

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability

maria.tullberg@vimian.com

+46 736 26 88 86

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 90 markets, has 1,000 employees and annual revenues of approximately EUR 280 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.

This information is information that Vimian Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-06-29 14:15 CEST.

Attachments

[Vimian Group AB \(publ\) CEO to step down at the end of the year](#)